Starting Monday morning, October 12, industry leaders in transcatheter cardiovascular innovation will convene at the Moscone Center in San Francisco. T3 Labs Executive Director and Program Director Deepal Panchal will be among the hundreds of attendees learning about and sharing their experiences with emerging cardiovascular therapies at TCT 2015.

“Learning about emerging transcatheter cardiovascular therapies and how we can translate that into the preclinical space and back; from concept to cure and vice versa is the highest value TCT provides,” Deepal said. “The more we learn about new devices and newly identified complications from existing devices, improves our ability to maximize the investment in preclinical models for our medical device testing sponsors.

“The potential to be part of groundbreaking, life-changing therapies by engaging with the leaders in the transcatheter innovation field is the top reason we attend TCT,” Deepal continued. “The odds on discovering and partnering with medical device innovators whose work in cardiovascular innovation will generate ‘first of its kind’ documentation or ‘first-in-man’ therapies is strong. We are always eager to learn about the latest developments and innovation in mitral valve technologies, drug eluting scaffold technologies, renal denervation, aortic valve and transcatheter aortic valve replacement [TAVR]. TCT is the place for that.”

T3 Labs sponsors enjoy high value preclinical results

T3 Labs partners Alizee Pathology published first of its kind documentation discovering that a progressive regenerative response occurs as early as 7 days after renal denervation, resulting in a poorly organized neuromatous regeneration.

T3 Labs sponsor Surefire Medical also enjoyed FDA 510(k) approval in just 76 days, a record for the company, for its direct to tumor embolization device Surefire Precision.

Designed by cardiologists for cardiologists and other medical device developers, T3 Labs is an industry leading preclinical CRO for cardiothoracic device testing and training. From structural heart, aortic valve therapies, renal denervation and more, T3 Labs has archived more than 50 GLP studies and supported more than 30 medical products achieving FDA regulatory approval. With 7 state of the art procedure areas, 3 top quality operating rooms, 1 fixed cath lab and all of the equipment necessary including C-arms, ECHO, Doppler, IVUS, OCT, micro-CT, MRI, CT and more, T3 stands ready to support cardiovascular innovation by helping the innovators in structural heart therapies maximize their investment in preclinical needs.

Connect with T3 Labs at TCT 2015

To connect with Andrew Stevenson or Deepal Panchal onsite at TCT October 12 – 14, email or